| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-01-03 | Sanofi Pasteur (France) Sutro Biopharma (USA - CA) | two undisclosed vaccine candidates | undisclosed | R&D |
undisclosed | Production agreement |
| 2013-01-03 | Cellular Dynamics (USA) AstraZeneca (UK) | iPSC-derived human cells | R&D |
R&D agreement | ||
| 2013-01-03 | Philogen (Italy) Pfizer (USA - NY) | Dekavil | rheumatoid arthritis, inflammatory bowel disease | licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2013-01-03 | CEVEC Pharmaceuticals (Germany) Vakzine Projekt Management (Germany) | CMV dense body project (human cytomegalovirus (CMV) vaccine) | prevention of cytomegalovirus infection | licensing |
Infectious diseases | Licensing agreement |
| 2013-01-02 | Evotec (Germany) Apeiron Biologics (Austria) | immunomodulatory lead compounds | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-12-27 | AstraZeneca (UK) CytImmune (USA) | CYT-6091 nanomedicine platform | solid tumours | R&D |
Cancer - Oncology | R&D agreement |
| 2012-12-21 | Biotec Pharmacon (Norway) Smith & Nephew (UK) | Woulgan® Biogel | treatment of chronic wounds including treatment of diabetic foot ulcer | collaboration |
Metabolic diseases | Collaboration agreement |
| 2012-12-21 | Roche (Switzerland) Precision System Science (Japan) | fully automated emulsion PCR instrument | development |
Production agreement | ||
| 2012-12-20 | CEVEC Pharmaceuticals (Germany) Yuhan Corporation (South Korea) | CAP-T™ and CAP® cell expression systems | licensing |
Licensing agreement | ||
| 2012-12-20 | AstraZeneca (UK) LegoChem Biosciences (South Korea) | novel antibiotics combining compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and LegoChem’s preclinical cephalosporin antibiotic programs | drug-resistant bacterial infections | R&D |
Infectious diseases | R&D agreement |
| 2012-12-19 | Glycovaxyn (Switzerland) GSK (UK) | new bacterial vaccines employing GlycoVaxyn’s bio-conjugation technology | R&D |
Infectious diseases | R&D agreement | |
| 2012-12-19 | Lonza (Switzerland) Sartorius Stedim Biotech (France) | cell culture media and buffers | development |
|||
| 2012-12-19 | AIMM Therapeutics (The Netherlands) Cosmo Pharmaceuticals (Italy) | oral diagnostic and therapeutic antibodies for gastrointestinal diseases | gastrointestinal diseases including colon carcinoma | development |
Gastrointestinal diseases - Cancer - Oncology | Development agreement |
| 2012-12-18 | Cellectis (France) University College of London (UK) | T-cell adoptive immunotherapy | leukemia | development |
Cancer - Oncology | Development agreement |
| 2012-12-18 | Arrowhead (USA) Shire (UK) | targeted peptide-drug conjugates (PDCs) | undisclosed | R&D |
Rare diseases | R&D agreement |
| 2012-12-18 | Ipsen (France) Oncodesign (France) Laboratory for Neurobiology and Gene Therapy (LNGT - KU Leuven Belgium) | new therapeutic agents against the LRRK2 Parkinson's disease target | Parkinson’s disease | R&D | Neurodegenerative diseases - CNS diseases | Research agreement |
| 2012-12-18 | Sartorius Stedim Biotech (France) Umetrics (Sweden) | software portfolio for optimization of biopharmaceutical development and manufacturing processes | commercialisation |
Commercialisation agreement | ||
| 2012-12-18 | AstraZeneca (UK) Fudan University (China) | leonurine | cardiovascular diseases | R&D |
Cardiovascular diseases | R&D agreement |
| 2012-12-17 | 4SC Discovery (Germany) BioNTech (Germany) | small molecule toll-like receptor (TLR) agonists to be used as anti-cancer immunotherapy | cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2012-12-17 | The Babraham Institute (UK) Karus Therapeutics (UK) | phosphatidylinositol-3-kinases (PI3K) inhibitors | inflammatory diseases, rheumatoid arthritis | R&D |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | R&D agreement |
